Good day readers! This week we’ve curated 20 GPCR papers, 3 new events, 9 industry news, and 3 job opportunities! Discover our comprehensive coverage of GPCRs, We welcome GPCR paper suggestions! Submit your publications to Hello@DrGPCR.com for consideration. This week's highlight: Dr. Matthew T Eddy and his team's research on A2A adenosine receptor activation by G protein and mutations. Are you looking to hire? Or maybe looking for your next opportunity? Our Chief Matchmaker, Mark Schmeizl, is here to assist you. Simply complete this form to get in touch with him. November Dr. GPCR Newsletter is out now. Subscribe for this month's video featuring Dr. Alix Rouault. Ensure to catch the upcoming episodes of Dr. GPCR Podcast featuring Dr. Neil Grimsey and Dr. Katarzyna Marcinkiewicz. Be sure to look at the Classified GPCR News from November 27th to December 3rd, 2023. GPCR Activation and Signaling DANGER Signals Activate G -Protein Receptor Kinases Suppressing Neutrophil Function and Predisposing to Infection After Tissue Trauma Single-molecule visualization of human A2A adenosine receptor activation by a G protein and constitutively activating mutations Distinct activation mechanisms of β-arrestin-1 revealed by 19F NMR spectroscopy Role of protease activated receptor 4 (PAR4) in mouse models of acute and chronic kidney injury GPCR Binders, Drugs, and more High-throughput virtual screening of potential inhibitors of GPR52 using docking and biased sampling method for Huntington's disease therapy Rational design of highly stabilized and selective adrenomedullin analogs Novel multi-target ligands of dopamine and serotonin receptors for the treatment of schizophrenia based on indazole and piperazine scaffolds-synthesis, biological activity, and structural evaluation Flavonoids as G Protein-coupled Receptors Ligands: New Potential Therapeutic Natural Drugs GPCRs in Cardiology, Endocrinology, and Taste Phenylacetyl glutamine (PAGln) enhances cardiomyocyte death after myocardial infarction through β1 adrenergic receptor Comparative transcriptomic analysis of mammary gland tissues reveals the critical role of GPR110 in palmitic acid-stimulated milk protein and fat synthesis GPCRs in Neuroscience Targeting sensory neuron GPCRs for peripheral neuropathic pain GPCRs in Oncology and Immunology Expression prevalence and dynamics of GPCR somatostatin receptors 2 and 3 as cancer biomarkers beyond NET: a paired immunohistochemistry approach The combination of brentuximab vedotin and chidamide synergistically suppresses the proliferation of T-cell lymphoma cells through the enhancement of apoptosis Methods & Updates in GPCR Research Modulating signalling lifetime to optimise a prototypical animal opsin for optogenetic applications Imaging flow cytometry of tumoroids: A new method for studying GPCR expression GPCR molecular dynamics forecasting using recurrent neural networks A method for multiple-sequence-alignment-free protein structure prediction using a protein language model Reviews, GPCRs, and more Potential of olfactory neuroepithelial cells as a model to study schizophrenia: A focus on GPCRs (Review) Structural and Molecular Insights into GPCR Function Fully activated structure of the sterol-bound Smoothened GPCR-Gi protein complex Deep Learning Dynamic Allostery of G-Protein-Coupled Receptors Industry News Sosei Heptares to take back GPCR agonist after GSK changes course All-rounder among receptors inspires drug research Tectonic Therapeutic Announces Start of First Clinical Program for GPCR-Targeted Biologic Trevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries Carmot Therapeutics Enters into Definitive Merger Agreement with Roche New Clinical Trial Explores Novel Target In Parkinson’s Treatment GPCR Events, Meetings, and Webinars January 16 - 19, 2024 | 23rd Annual PEP Talk February 3 - 7, 2024 | SLAS2024 International Conference and Exhibition February 11 - 14, 2023 | 2024 BPS Annual Meeting March 5 - 7, 2024 | 3rd GPCRs - Targeted Drug Discovery Summit March 23 - 24, 2024 | Ligand Recognition and Molecular Gating Seminar March 24 - 29, 2024 | Ligand Recognition and Molecular Gating Conference April 1 - 4, 2024 | 19th Annual Drug Discovery Chemistry April 4 - 7, 2024 | American Physiology Summit April 5 - 10, 2024 | AACR Annual Meeting April 22 - 23, 2024 | Endocrine Metabolic GPCRs May 13 - 17, 2024 | 20th Annual PEGS Boston Summit May 16 - 19, 2024 | ASPET 2024 May 27 - 29, 2024 | SLAS Europe 2024 Conference and Exhibition June 2 - 7, 2024 | Chemotactic Cytokines NEW June 9 - 14, 2024 | 2024 Phosphorylation and G-Protein Mediated Signaling Networks NEW June 25 - 29, 2024 | FENS Forum 2024 October 2 - 4, 2024 | 9th GPCRs in Medicinal Chemistry NEW October 23 - 25, 2024 | 11th Adhesion GPCR Workshop July 12 - 17, 2026 | 20th World Congress of Basic and Clinical Pharmacology 2026 GPCR Jobs NEW Principal scientist – oncology biomarker expert NEW Postdoctoral Fellow NEW Scientific Assistant Scientist Lead Researcher Post-Doctoral Fellow Sr Scientist in Obesity, Muscle, and Metabolism Post-Doctoral Fellow Explore Dr. GPCR Ecosystem

Subject in TRV045 Proof-of-Concept Trial Evaluating S1PR Mechanism of Action and Target Engagement Novo Nordisk's GLP-1 for Type II diabetes approved for first-line treatment The Lundbeck Foundation is awarding

Submit a logo design by Nov 1st on the Logo Contest page. relatedness Industry News Nobel Laureates Highlight Symposium Celebrating Lefkowitz’s 50 Years at Duke Novo Nordisk stops Ozempic kidney trial after early signs of success Sosei and PharmEnable extend neurological

Health (RHU) SPRINT consortium grant to progress its proprietary CCR8 antibody candidate to the clinic Novo Radioligand Therapy Production Plant Novartis’ Lutathera reduces disease progression risk in GEP-NET trial Novo Nordisk hits $500 billion in market value as it flags soaring demand for Wegovy, Ozempic Dr.

Immunotherapy Drug HTL0039732 Exscientia Business Update for Second Quarter and First Half of 2023 Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes

July 2022 "I’m happy to share that I’m starting a new position as Scientific co-founder LASEREDD Therapeutics

University’s first female Professor of Chemistry, former president of the Royal Society of Chemistry and Founder highly prestigious international award – exemplified by the fact that other winners this year are the co-founders

Most founders are prepared for this on a technical level. Founders feel the pressure to hold everything together. Founders who recognize this early stop asking whether a candidate is impressive. How Founders Can Hire for Survival Without Overengineering It 👉 Once founders recognize that survival For founders, this is not about fixing past hires.

Breakthroughs this week:  5-MeO-DMT: the "God Molecule"; Novo Nordisk looks to next generation of obesity

Breakthroughs this week: Novo Nordisk cuts Ozempic® cost; Nxera launches obesity pipeline; Superluminal–Lilly

Submit your logo design by Nov 1st on the Logo Contest page. Company in Immuno-Oncology, Domain Therapeutics, Presents Groundbreaking Advancements at ESMO 2023 Novo Nordisk to Buy Hypertension Treatment from KBP Biosciences Exscientia to Present New Preclinical Data

and Provides Business Update Crinetics Pharmaceuticals: Paltusotine Phase 3 Data Presented At ENDO Novo Nordisk to Acquire Inversago Pharma GPCR Events, Meetings, and Webinars NEW Antiverse: Reimagining Therapeutic

Indeed, incretin-based drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound are advancing diabetes

Michel Bouvier, J Silvio Gutkind, and team found that Gαs is essential for GRK selectivity and gene regulation Channel Drug Developer Maxion Therapeutics Appoints Eva-Lotta Allan as Chair of its Board of Directors Novo Nordisk and Evotec collaborate to launch LAB eN², a translational drug discovery accelerator, to address

enable the identification of selective antagonists Industry News Inside the FDA's Form 483 findings at Novo Nordisk's North Carolina semaglutide plant Excellerate Bioscience Announces Site Relocation AI can help

Raised To Discover And Advance Novel Oral Small Molecule Medicines Targeting G Protein-Coupled Receptors Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults

Research Collaboration with Amgen to Discover Small Molecule Therapeutics using Artificial Intelligence Novo Nordisk Invests 42 Billion Danish Kroner in New Manufacturing Facilities Addex ADX71149 Epilepsy Phase

December 2021 OMass Therapeutics's founder, Carol Robinson, has been awarded the prestigious Louis-Jeantet Prize for Medicine 2022 by the Louis-Jeantet Foundation and the 2022 Benjamin Franklin Medal in Chemistry from The Franklin Institute "Huge congratulations to our founder, Carol Robinson, who has been awarded the prestigious Louis-Jeantet Prize for Medicine 2022 by the Louis-Jeantet Foundation and the 2022 Benjamin

May 2022 "We are thrilled to announce that our co-founder Margaux Duchamp has been selected as a 30 under

Breakthroughs this week: Decoding ADGRE5 signaling; Eli Lilly’s obesity pill vs Novo’s Wegovy; Certa GPCRs in the spotlight; receptor motion tracking tools; obesity treatment race between Eli Lilly and Novo

April 2022 John Streicher talks about his work on terpenes found in cannabis as these may be a novel

This week’s feature goes straight to the foundation: how system-level GPCR thinking  protects discovery Week in Premium: Sneak Peek Industry insights:  Lilly cuts Zepbound prices; Lilly hits $1T valuation; Novo

We’ve shaped everything we do around three interconnected ecosystems: Free , Premium , and Foundry. Strengthening the Foundation You already know our Free Ecosystem  — the podcast, blogs, and Flash News GPCR Foundry  — our R&D and biotech hub designed to bridge GPCR science with execution. The Dr. GPCR Foundry: Science Meets Execution The Foundry is where we bring together biotech innovators, Venture With appreciation and excitement, Yamina Berchiche Founder & CEO, Dr. GPCR About Dr. GPCR Dr.

In this conversation ► 00:00 The amylin receptor challenge, and why it matters now ► 00:40 The Novo dual-agonist

Yamina Berchiche , Founder and CEO of Dr. GPCR. Reproducible data are foundational to progress in GPCR biology, target validation, and translational reinforces the importance of transparency and community engagement in strengthening the experimental foundations antibody specificity and the reproducibility of GPCR data, contributing to a more robust and reliable foundation About GeneTex GeneTex is a multinational antibody manufacturer founded in 1997, with research and manufacturing

Biologics announce manufacturing agreement  to advance novel anti-CCR8 antibody  for cancer immunotherapy Novo

Your scientific thinking built the foundation, but leadership is what scales it. Let’s unpack the three core “rules” most scientific founders unconsciously carry into their companies In startups, waiting too long for certainty can destroy your momentum . 👉 Biotech founders often delay Founders who keep operating like researchers often create internal confusion. The transition between the two isn’t automatic, even for the most capable founders.

Therapeutics with Generative AI Nxera Pharma receives approval of insomnia drug in Japan Lilly and Novo and UK and Announces the Nomination of Clinical Candidate Against MC2 Call for GPCR Papers Deadline: Nov

Industry insights:  Fresh selectivity datasets on openMe; Novo’s obesity dominance faces new challengers

Welcome to Terry’s Corner , where foundational pharmacology is demystified by someone who’s spent over just look at the data—learn how to read the story it’s telling. 👉 Start your journey with Terry’s foundational